07.04.2017
Biotest AG DE0005227235
DGAP-Adhoc: Biotest AG: Takeover Offer: Chinese strategic investor Creat to make a voluntary public takeover offer for the shares of Biotest AG
DGAP-Ad-hoc: Biotest AG / Key word(s): Merger
Biotest AG: Takeover Offer: Chinese strategic investor Creat to make a
voluntary public takeover offer for the shares of Biotest AG
07-Apr-2017 / 12:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
/
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)
Takeover Offer: Chinese strategic investor Creat to make a voluntary public
takeover offer for the shares of Biotest AG
Dreieich, 7 April 2017. Biotest AG, Tiancheng International Investment
Limited, Hong Kong, and Blitz 17-623 AG (in future: Tiancheng (Germany)
Pharmaceutical Holdings AG), affiliated companies controlled by Creat Group
Corporation, have signed a Business Combination Agreement today. Tiancheng
(Germany) Pharmaceutical Holdings AG announced today its decision to make a
voluntary public takeover offer for all outstanding ordinary and preference
shares of Biotest AG for EUR 28.50 per ordinary share and EUR 19.00 per
preference share in an all-cash transaction. Subject to the terms and
conditions of the Business Combination Agreement and their statutory
fiduciary duties, in particular the review of the offer document to be
published by Tiancheng (Germany) Pharmaceutical Holdings AG, Biotest AG's
Management Board and Supervisory Board welcome and support the voluntary
takeover offer. The offer will be subject to a minimum acceptance threshold
of 75 percent of all ordinary shares as well as regulatory approvals.
Biotest AG has been informed that Biotest AG's majority shareholder, OGEL
GmbH, supports the transaction and has agreed with Tiancheng International
Investment Limited, Hong Kong, to irrevocably accept the offer and to tender
its shares, which represent 50.61 percent of all outstanding ordinary
shares.
The Management Board and the Supervisory Board of Biotest AG will provide a
statement concerning this offer pursuant to their statutory duties upon
publication of the offer document.
Biotest Aktiengesellschaft
Board of Management
Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.com
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: [email protected]
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: [email protected]
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich,
Stuttgart
Contact:
Dr. Michael Ramroth
Chief Financial Officer
Biotest AG
Landsteinerstr. 3
63303 Dreieich
Tel. +40 6103 801 338
Fax: +49 6103 801 347
[email protected]
---------------------------------------------------------------------------
07-Apr-2017 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [email protected]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of Announcement DGAP News Service
---------------------------------------------------------------------------
563247 07-Apr-2017 CET/CEST
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biotest AG ISIN: DE0005227235 können Sie bei EQS abrufen
Gesundheit , 522723 , BIO3 , XETR:BIO3